{
    "code": "52027499",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027499",
    "time": "2020-02-26 06:35:49",
    "許可證字號": "衛部藥輸字第027499號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "112\/08\/30",
    "發證日期": "107\/08\/30",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202749903",
    "中文品名": "&quot;瑞士&quot;億珂膠囊140毫克",
    "英文品名": "&quot;Switzerland&quot; Imbruvica Capsules 140mg",
    "適應症": "1.被套細胞淋巴瘤 IMBRUVICA適用於對先前治療無效或復發的被套細胞淋巴瘤Mantle Cell Lymphoma (MCL)成年病人。2.慢性淋巴球性白血病\/小淋巴球性淋巴瘤 IMBRUVICA適用於治療慢性淋巴球性白血病Chronic Lymphocytic Leukemia (CLL)\/小淋巴球性淋巴瘤Small Lymphocytic Lymphoma (SLL)成年病人。3. 17p缺失性之慢性淋巴球性白血病\/小淋巴球性淋巴瘤 IMBRUVICA適用於治療患有17p缺失性之慢性淋巴球性白血病Chrnic Lymphocytic Leukemia (CLL)\/小淋巴球性淋巴瘤(SLL)的成年病人。4. Waldenstrom氏巨球蛋白血症 IMBRUVICA適用於治療先前曾接受至少一種治療或於第一線治療時不適合接受化學免疫治療(chemo-immunotherapy)的Waldenstom氏巨球蛋白血症Waldenstrom's macroglobulinemia (WM)的成年患者。5.邊緣區淋巴瘤 IMBRUVICA適用於治療須接受全身性治療且先前曾接受至少一種抗CD20療法的邊緣區淋巴瘤Marginal Zone Lymphoma (MZL)成年患者。6.慢性移植體抗宿主疾病 IMBRUVICA適用於治療使用一線或多線全身性療法治療失敗後的慢性移植體抗宿主疾病chronic Graft-Versus-Host Disease (cGVHD)成年患者。",
    "劑型": "130膠囊劑",
    "包裝": "8-1000粒塑膠瓶裝(HDPE)",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "監視中學名藥",
    "監視期限": "",
    "主成分略述": "Ibrutinib",
    "限制項目": "02輸　入 25監視中學名藥",
    "申請商名稱": "1507401100  嬌生股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號10樓及11樓",
    "主製造廠": [
        {
            "製造廠名稱": "FCH0015000  CILAG AG.",
            "製造廠廠址": "HOCHSTRASSE 201 CH-8200 SCHAFFHAUSEN SWITZERLAND",
            "製造廠公司地址": "VIA M. BUONARROTI 23 20093 COLOGNO MONZESE,ITALY",
            "製造廠國別": "SWITZERLAND",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6132061151  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013005100",
            "成分名稱": "Ibrutinib",
            "含量描述": "",
            "含量": "140.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Imbruvica Capsules 藥物外觀照片-108-06-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=002&Type=10"
        },
        {
            "title": "Imbruvica capsules-108-03-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "1204_億珂膠囊140毫克(瑞士廠)-仿單-108-06-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=002&Type=9"
        },
        {
            "title": "[打樣版](Chi) TW PI_Imbruvica USPI Dec2017 and CCDS 16Aug2016 (MCL3001 result)_v1901(新址)-108-03-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=001&Type=9"
        },
        {
            "title": "Imbruvica Cilag AG 標籤_120 Caps-108-06-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=004&Type=8"
        },
        {
            "title": "Imbruvica Cilag AG 標籤_90 Caps-108-06-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=003&Type=8"
        },
        {
            "title": "Imbruvica Cilag AG 外盒_120 Caps-108-06-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=002&Type=8"
        },
        {
            "title": "Imbruvica Cilag AG 外盒_90 Caps-108-06-17.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027499&Seq=001&Type=8"
        }
    ]
}